From a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues, and in soft tissues.
Assess safety and efficacy of these newly developed antimicrobial technologies.
Enhance the therapeutic efficacy of current antibiotics by combination therapy.
Develop a new workflow based on AOPs (adverse outcome pathways) of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market.
Maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HCPs.